Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in TEM.
← Back to Free Index

TEM

Analysis as of: 2026-03-28
Tempus AI, Inc.
Tempus provides genomic diagnostics, clinical workflow software, and multimodal data products to physicians, health systems, and life sciences companies.
ai healthcare medical devices software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Regulated data flywheel with room to mature
The core bet is that AI makes proprietary clinical data and regulated diagnostics more valuable, not less. The upside is meaningful if Tempus converts that advantage into higher-margin software and pharma revenue without losing discipline on reimbursement, cash burn, or dilution.

Analysis

Thesis
Tempus can compound into a larger precision-medicine operating system because AI lowers the cost of extracting value from its multimodal dataset while regulated assays, workflow integration, and pharma collaborations keep value capture from collapsing into commodity software.
Last Economy Alignment
Tempus benefits as AI makes its proprietary data, regulated tests, and embedded workflows more valuable; low seat exposure and strong switching costs limit UI commoditization.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.5x (from 5 most recent analyses)
Reasoning
I underwrite a premium but not peak multiple because by 2031 Tempus should look less like a loss-making diagnostics consolidator and more like a hybrid of regulated testing, embedded workflow software, and data/licensing infrastructure. If diagnostics keeps feeding the data flywheel and pharma collaborations convert into repeatable revenue, investors can still pay up for mix quality, retention, and cash generation, though not at pure-software extremes.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The opportunity is attractive, but Tempus still has to prove three linked steps: diagnostics stability, real EBITDA and cash-flow inflection, and repeatable monetization of its pharma and data layer. The main failure modes are reimbursement friction, financing or dilution needs, and the market deciding the software layer deserves only a diagnostics-style multiple.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.62
They control a hard-to-copy mix of clinical data, regulated tests, and hospital workflow slots, so cheaper AI makes their products more useful rather than obsolete. The risk is that each new clinical product still needs reimbursement and regulatory wins, which slows how fast the flywheel can turn.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$78.20
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case